A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring

Canadian Journal of Cardiology

Volumn 16, Issue 9, 2000, Pages 1123-1132

  Littlejohn, T ^a   Mroczek, W ^a   Marbury, T ^a   VanderMaelen, C P ^a   Dubiel, R F ^a  

^a Piedmont Medical Research Associates   (United States)

Author keywords

Blood pressure; Hypertension; Receptors

Indexed keywords

TELMISARTAN; VALSARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PAIN; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

ADMINISTRATION, ORAL; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PATIENT COMPLIANCE; SINGLE-BLIND METHOD; TETRAZOLES; VALINE;

EID: 0033784560     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Organ protection and optimal blood pressure control
2. Why ambulatory blood pressure monitoring?
3. The drug defaulter
4. Some problems with antihypertensive drug studies in the context of the new guidelines
5. Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists
6. To be taken as directed
7. Drug therapy: Patient compliance
8. Attitudes of patients with hypertension or arthritis towards the frequency of medication administration
9. Patient compliance and therapeutic coverage: Comparison of amlodipine and slow release nifedipine in the treatment of hypertension
10. Pharmacological characterisation of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277
11. The incidence of cough: A comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist
12. Telmisartan
13. Clinical advantage of valsartan
14. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension
15. 14C]-radiolabelled telmisartan, a potent angiotensin II antagonist, in healthy male subjects
16. 1 receptor antagonist telmisartan in patients with mild to moderate hypertension
17. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man
18. Accuracy of the SpaceLabs 90297 determined by the British Hypertension Society Protocol
19. Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry
20. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials
21. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension
22. Average daily blood pressure, not office blood pressure, determines cardiac function in patients with hypertension
23. Multiple standardized clinic blood pressures may predict left ventricular mass as well as ambulatory monitoring
24. Silent cerebrovascular disease in the elderly. Correlation with ambulatory pressure
25. Ambulatory blood pressure in microalbuminuric type 1 diabetic patients
26. The prognostic value of ambulatory blood pressures
27. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension
28. Twenty-four hour blood pressure monitoring to compare the efficacy and duration of action of the ATII antagonist telmisartan to amlodipine
29. Circadian variation in the frequency of sudden cardiac death
30. Circadian variation in the frequency of onset of acute myocardial infarction
31. Circadian variation of total ischaemic burden and its alteration with antianginal agents
32. Biorhythms and chronotherapy in cardiovascular disease
33. Circadian rhythms in cardiovascular disease
34. Heart rate as a risk factor for atherosclerosis and cardiovascular mortality: The effect of antihypertensive drugs
35. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension
36. Angiotensin II receptor inhibition. A new therapeutic principle
37. Angiotensin receptors and their antagonists
38. Angiotensin receptor antagonists: Focus on losartan
39. Clinical profile of the novel angiotensin II type blocker candesartan cilexetil
40. Clinical overview of irbesartan: Expanding the therapeutic window in hypertension